Pamidronic acid
Pamidronate (pamidronic acid) is a small molecule pharmaceutical. Pamidronic acid was first approved as Aredia on 1991-10-31. It is used to treat extramammary paget disease, hypercalcemia, osteolysis, and postmenopausal osteoporosis in the USA. The pharmaceutical is active against farnesyl pyrophosphate synthase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Pamidronate (discontinued: Aredia, Pamidronate)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pamidronate disodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PAMIDRONATE DISODIUM | Hikma Pharmaceuticals | N-021113 RX | 2002-03-04 | 2 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| pamidronate disodium | ANDA | 2023-12-19 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| postmenopausal osteoporosis | EFO_0003854 | D015663 | — |
| hypercalcemia | HP_0003072 | D006934 | E83.52 |
| osteolysis | HP_0002797 | D010014 | M89.5 |
| extramammary paget disease | — | D010145 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
48 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 5 | 1 | 4 | — | 10 |
| Osteoporosis | D010024 | HP_0000939 | M81.0 | 1 | 2 | — | 1 | 3 | 6 |
| Metabolic bone diseases | D001851 | HP_0000938 | — | — | 1 | — | 4 | 1 | 6 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 2 | 1 | 2 | — | 5 |
| Bone diseases | D001847 | — | M89.9 | — | — | — | 3 | 1 | 4 |
| Osteogenesis imperfecta | D010013 | — | Q78.0 | — | 1 | 1 | 1 | 1 | 4 |
| Neoplasms | D009369 | — | C80 | 1 | 1 | — | 1 | — | 3 |
| Prostatic neoplasms | D011471 | — | C61 | — | — | — | 2 | — | 2 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | — | 1 | — | 1 | — | 2 |
| Spondylitis | D013166 | — | M46.9 | — | — | — | 2 | — | 2 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 2 | 6 | 2 | — | — | 9 |
| Plasma cell neoplasms | D054219 | — | — | 2 | 5 | 2 | — | — | 8 |
| Plasmacytoma | D010954 | — | C90.3 | 1 | 2 | 1 | — | — | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Low back pain | D017116 | HP_0003419 | M54.5 | 2 | 2 | — | — | — | 3 |
| Back pain | D001416 | HP_0003418 | M54 | 2 | 2 | — | — | — | 3 |
| Second primary neoplasms | D016609 | — | — | — | 2 | — | — | — | 2 |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | — | 1 | — | — | 1 | 2 |
| Pain | D010146 | EFO_0003843 | R52 | 1 | 1 | — | — | 1 | 2 |
| Residual neoplasm | D018365 | — | — | — | 1 | — | — | — | 1 |
| Drug therapy | D004358 | — | — | — | 1 | — | — | — | 1 |
| Bone neoplasms | D001859 | EFO_0003820 | D16 | — | 1 | — | — | — | 1 |
| Bone marrow diseases | D001855 | — | — | — | 1 | — | — | — | 1 |
| Osteosarcoma | D012516 | — | — | — | 1 | — | — | — | 1 |
Show 5 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | 1 | — | — | — | — | 1 |
| Acquired hyperostosis syndrome | D020083 | EFO_1001164 | — | 1 | — | — | — | — | 1 |
| Arthroplasty | D001178 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteonecrosis | D010020 | EFO_0004259 | M87 | — | — | — | — | 3 | 3 |
| Bisphosphonate-associated osteonecrosis of the jaw | D059266 | — | — | — | — | — | — | 2 | 2 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | — | — | — | 2 | 2 |
| Femoral fractures | D005264 | — | S72 | — | — | — | — | 1 | 1 |
| Healthy volunteers/patients | — | — | — | — | — | — | — | 1 | 1 |
| Bone density | D015519 | EFO_0003923 | M85 | — | — | — | — | 1 | 1 |
| Femur head necrosis | D005271 | — | — | — | — | — | — | 1 | 1 |
| Necrosis | D009336 | — | — | — | — | — | — | 1 | 1 |
| Cerebral palsy | D002547 | — | G80 | — | — | — | — | 1 | 1 |
| Spinal dysraphism | D016135 | EFO_1001210 | Q05 | — | — | — | — | 1 | 1 |
Show 1 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Pamidronic acid |
| INN | pamidronic acid |
| Description | Pamidronate is a phosphonoacetic acid. |
| Classification | Small molecule |
| Drug class | calcium metabolism regulators |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NCCC(O)(P(=O)(O)O)P(=O)(O)O |
Identifiers
| PDB | — |
| CAS-ID | 40391-99-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL834 |
| ChEBI ID | — |
| PubChem CID | 4674 |
| DrugBank | DB00282 |
| UNII ID | OYY3447OMC (ChemIDplus, GSRS) |
Target
Agency Approved
FDPS
FDPS
Organism
Homo sapiens
Gene name
FDPS
Gene synonyms
FPS, KIAA1293
NCBI Gene ID
Protein name
farnesyl pyrophosphate synthase
Protein synonyms
(2E,6E)-farnesyl diphosphate synthase, Dimethylallyltranstransferase, Farnesyl diphosphate synthase, farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase, FPP synthase, FPP synthetase, Geranyltranstransferase
Uniprot ID
Mouse ortholog
Fdps (110196)
farnesyl pyrophosphate synthase (Q920E5)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,076 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
14,275 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use